Cure8 trial brief
The study aims to map the specific peptide targets of T cells driving organ inflammation in autoimmune diseases, which could guide development of antigen-specific, tolerogenic treatments relevant to Crohn's disease and other IBD.
Patients with Crohn's disease or ulcerative colitis, IBD clinicians and researchers studying T cell targets or antigen-specific therapies, and others interested in autoimmune disease biomarker discovery.
The study enrolled multiple autoimmune conditions and planned paired tissue and blood sampling during standard clinical procedures (colonoscopy/biopsy for IBD, endoscopy for celiac disease, lumbar puncture for MS, arthrocentesis or surgical tissue for spondyloarthritis, skin biopsy for scleroderma).
Researchers planned to isolate expanded T cell clones from inflamed tissue and define their peptide targets with a genome-wide TScan technology. The stated goal is to build a catalogue of TCRs and their targets to inform tolerogenic therapy discovery.
This is a clinicaltrials.gov trial record for a completed observational biospecimen-collection study; the page describes objectives, cohorts, and procedures but does not report results. The technology described (TScan) is a research platform for identifying TCR targets.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.
Shows which IBD comorbidities may be driven in part by shared inherited genetic risk and which likely reflect non-genetic factors, information that could shape future risk stratification and screening approaches for...
This study highlights that people who go on to develop myasthenia gravis had higher rates of other autoimmune diagnoses in the years beforehand, which may be relevant for clinicians tracking autoimmune comorbidity...
